Loading company…
Resverlogix Corp. is a Calgary developer of epigenetic therapeutics, led by the late-stage drug apabetalone.
Headquartered in Calgary, Canada, Resverlogix Corp. develops epigenetic therapeutics for chronic diseases, with a focus on cardiovascular conditions and post COVID-19 complications. Its lead product, apabetalone, is in late-stage clinical evaluation, including the global Phase 3 BETonMACE trial. The company has completed three significant funding deals, the latest a PIPE round for CAD 24.70 mn led by NGN Capital on April 12, 2018.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in